Purpose:
The primary purpose of the BabyCove Study is to evaluate the safety and reactogenicity of 2 dose levels of mRNA-1273.214 vaccine administered as 2 doses 8 weeks apart in participants aged 12 weeks to < 6 months.
What to Expect:
Participation in the BabyCove Study lasts approximately 15 months which includes 1 month for screening, 2 months for dosing, and 12 months of follow-up after the second dose.
The study doctor and medical staff will talk to you and your child about additional medical support that your child will receive if he/she experiences COVID-19 symptoms at any time while in this clinical trial. Insurance is not needed to join this clinical trial, and compensation for your family’s time will be available.
Eligibility Criteria:
Participant must:
Participant must not:
Length / Duration:
Participation in the BabyCove Study lasts approximately 15 months and includes phone calls, telemedicine visits, and multiple visits to the study site.
Location:
13229 Hillsdale Lane, Kissimmee, Florida 34741, United States
Who should you contact:
Recruitment Department: (407) 350-3979
Tell us a little bit about yourself. We will contact you for additional information to determine your eligibility for current and future studies.
3229 Hillsdale Lane, Kissimmee, Florida 34741, United States
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2023 Kissimmee Clinical Research- All rights reserved
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.